A study published in the Journal of Extracellular Vesicles in April 2026 by researchers at Texas A&M University has produced results that would have seemed implausible just a few years ago.
A nasal spray containing microscopic particles derived from human neural stem cells reversed markers of brain aging in older mice.
Memory improved.
Inflammation dropped.
Cognitive function was measurably restored.
And the benefits appeared after just two doses, persisting for months.
“We are seeing the brain’s own repair systems switch on, healing inflammation and restoring itself,” said Ashok Shetty, professor of cell biology and genetics at Texas A&M. “As we develop and scale this therapy, a simple, two-dose nasal spray could one day replace invasive, risky procedures or maybe even months of medication.”
The treatment targets something called neuroinflammaging, a term that describes the slow, smouldering inflammation that builds in the brain over decades of aging, long before any symptoms of dementia appear.
And that timing, the targeting of a process that precedes Alzheimer’s by years or even decades, is what makes this research genuinely different from most of what has come before.
The Fire That Burns Before the Symptoms Begin
Most people think of Alzheimer’s as a disease that begins when memory starts to fail.
Science tells a very different story.
By the time a person notices the first signs of cognitive decline, the underlying biological damage in their brain has typically been building for 10 to 20 years.
The amyloid plaques that accumulate between neurons, the tau tangles that form inside them, the loss of synaptic connections that gradually erodes the brain’s ability to communicate with itself: all of these processes are well underway long before anyone notices that something is wrong.
Scientists call this slow-burning process neuroinflammaging, a combination of neuroinflammation and aging, and for decades it was thought to be the inevitable price of growing older.
Neuroinflammaging is driven primarily by a type of brain immune cell called microglia.
Microglia are the brain’s resident immune cells, responsible for surveilling the neural environment, clearing cellular debris, removing damaged proteins, and responding to threats.
In a young, healthy brain they perform this function quietly and efficiently.
As the brain ages, something goes wrong.
Once activated, microglia show changes in their morphology and function. Microglial dysfunction caused by prolonged amyloid-induced activation may contribute to Alzheimer’s disease.
The microglia that should be clearing harmful material become chronically overactivated.
Instead of resolving threats and returning to a surveillance state, they remain in a state of persistent alarm, releasing inflammatory signals that damage the very neurons they are supposed to protect.
The result is a self-reinforcing cycle of inflammation and neurodegeneration that builds slowly over years and eventually tips the brain past a threshold from which it cannot recover.
This smouldering inflammation creates a persistent brain fog that makes it harder to think, form new memories or even adapt to new environments, all the while increasing the risk of disorders like Alzheimer’s disease.
Two specific molecular pathways sit at the heart of this inflammatory cascade.
The first is the NLRP3 inflammasome, a protein complex inside microglia that acts as an alarm system, triggering the release of powerful inflammatory signals when it detects damage or threat.
Research published in Frontiers in Neurology has shown that NLRP3 activation is a key driver of the chronic neuroinflammation that characterises Alzheimer’s disease, and that it begins operating long before plaques and tangles appear.
The second is the cGAS-STING pathway, a cellular detection system that normally monitors for viral DNA but becomes dangerously overactive in the aging brain when damaged mitochondria leak their own DNA into the cell’s cytoplasm.
Stimulation of the cGAS-STING pathway induces microglial dysfunction and sterile inflammation, which exacerbates Alzheimer’s disease. STING activation was found to be necessary for microglial NLRP3 activation, proinflammatory responses, and type-I interferon responses.
The Texas A&M nasal spray is the first treatment to directly target both of these pathways simultaneously using a delivery method simple enough for a patient to use at home.
What the Spray Actually Contains
The active ingredient in the spray is not a drug in the conventional sense.
It is a collection of extracellular vesicles, tiny membrane-enclosed particles produced by human neural stem cells.
Extracellular vesicles are structures that cells use to communicate with each other, carrying proteins, RNA, and other molecular signals that can alter the behaviour of cells they encounter.
Neural stem cells, which are the cells responsible for generating new neurons in the developing brain, produce extracellular vesicles with a particularly potent anti-inflammatory cargo.
The idea behind the therapy is to harness that natural communication system.
Rather than delivering a drug molecule that targets a specific protein, the extracellular vesicles deliver a complex mixture of naturally occurring signals that can shift microglia from a destructive, inflammatory state back toward their normal housekeeping function.
“This approach is effective because the cargo carried by these extracellular vesicles could reduce the neuropathological changes in the brain,” says Ashok K. Shetty, University Distinguished Professor and associate director at the Institute for Regenerative Medicine at Texas A&M.
The nasal route of delivery is not incidental.
Getting therapeutic molecules into the brain is one of the most difficult challenges in neuroscience, because of a protective structure called the blood-brain barrier, a tightly regulated interface between the bloodstream and the brain that blocks most large molecules from crossing.
Intravenous or oral delivery of most neurological drugs results in the vast majority of the drug being broken down or blocked before it ever reaches the brain.
The nasal passage offers a direct anatomical shortcut, with nerve fibres connecting the upper nasal cavity to the olfactory bulb and from there directly into the brain’s deeper structures, bypassing the blood-brain barrier entirely.
The hippocampus, the brain’s primary memory centre and the region most severely affected in the early stages of Alzheimer’s, is accessible via this route.
How the Study Was Conducted
The Texas A&M team, led by Dr. Shetty, focused their experiments on aged mice at 18 months of age, which is roughly equivalent to a 60-year-old human, at the stage where the slow fire of neuroinflammaging is already burning but before overt neurodegeneration has set in.
This age range was chosen deliberately.
Current treatments have not been effective at stopping or reversing brain changes linked to neuroinflammaging.
The researchers wanted to test whether their spray could intervene at the stage where the inflammatory damage is occurring but has not yet produced irreversible consequences.
Mice received the nasal spray treatment and were then evaluated against untreated age-matched controls across a battery of tests measuring inflammation markers, cognitive function, and memory.
Compared with untreated mice, those given the spray showed reduced markers of brain inflammation and improvements in memory and cognitive function. The benefits appeared within weeks and persisted for months after just two doses.
The cellular level findings were equally striking.
The treatment significantly changed microglia gene expression and reduced multiple harmful proinflammatory proteins without affecting the microglia’s ability to continue clearing the protein buildup related to Alzheimer’s.
That last point is crucial and worth emphasising.
The spray did not simply shut down the microglia.
It recalibrated them.
The microglia remained active and continued clearing amyloid-related proteins, their essential housekeeping function, while losing their destructive inflammatory overactivity.
This balance between clearing harmful material and not causing inflammatory damage is extremely difficult to achieve with conventional drugs, which tend to either suppress the immune cells too broadly or leave the inflammatory pathways largely intact.
Findings From the Study
The study found that the intranasal extracellular vesicle therapy specifically restrained two of the key inflammatory pathways most implicated in Alzheimer’s: the NLRP3 inflammasome and the cGAS-STING pathway.
The findings, published in the Journal of Extracellular Vesicles, could reshape the future of neurodegenerative therapies and may even change how scientists think about brain aging itself.
The full publication details, titled Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus, confirm that the treatment achieved gene-level changes in microglial activity in the hippocampus specifically, the brain region most critical to memory formation and the first to suffer in Alzheimer’s.
The researchers also believe the treatment’s potential extends beyond Alzheimer’s.
Lead researcher Ashok Shetty has filed a patent on the intranasal application of neural stem cell-derived extracellular vesicles for treating Alzheimer’s and other neurological and neurodegenerative disorders.
The underlying mechanism, dampening chronic microglial overactivation through naturally derived vesicles, could theoretically apply to Parkinson’s disease, ALS, and other neurodegenerative conditions where neuroinflammation plays a central role.
But Here Is What Most Alzheimer’s Research Has Been Getting Wrong
For decades, the dominant theory of Alzheimer’s held that amyloid plaques were the primary cause of the disease.
Clear the plaques, the thinking went, and you stop the disease.
Drug after drug was developed to remove amyloid from the brain, and drug after drug failed in clinical trials, often spectacularly.
Even the most recently approved amyloid-clearing drugs, lecanemab and donanemab, which do successfully reduce plaque burden, offer only modest clinical benefit at considerable cost and risk.
The reason, increasingly clear from research conducted over the past decade, is that amyloid plaques are not the beginning of the story.
They are closer to the middle.
Evidence has accumulated that neuroinflammation, driven by chronically overactivated microglia, begins years before significant amyloid accumulation occurs, and may in fact drive the amyloid accumulation rather than being driven by it.
Recent evidence suggests that neuroinflammation mediated through increased levels of pro-inflammatory products released from innate immune cells, particularly microglia, contributes to Alzheimer’s and precedes amyloid plaque deposition and disease onset.
If that sequence is correct, then targeting amyloid after it has already formed is like mopping the floor while the tap is still running.
The tap is neuroinflammaging.
The Texas A&M nasal spray goes after the tap.
By targeting the NLRP3 and cGAS-STING pathways in microglia during the pre-symptomatic inflammatory phase, the treatment is designed to intervene at the biological stage that precedes and precipitates everything else that makes Alzheimer’s devastating.
The prospect of early interventions targeting neuroinflammation offers a potentially transformative approach to combating Alzheimer’s disease. By identifying and addressing inflammation at the earliest stages, it might be possible to halt or significantly delay the onset of symptoms such as amyloid plaques and tau tangles.
How This Applies to Real Life
The most immediate practical question for most people reading this is a simple one: how far away is this from being available?
The answer is that significant distance remains.
The current study was conducted in mice, and the history of Alzheimer’s research is littered with treatments that worked brilliantly in animal models and failed in human trials.
The biology of Alzheimer’s in living human brains is considerably more complex than what animal models can capture, particularly given the decades-long timeline of the disease and the enormous variation between individuals in genetic risk, lifestyle factors, and the specific pattern of biological changes.
Human trials will be needed to establish whether the therapy is safe, whether the benefit seen in mice translates to people, and crucially, who should receive it and when.
That last question is not straightforward.
If the target is neuroinflammaging in its early stages, the population that could benefit most is not people who already have Alzheimer’s symptoms.
It is people in their 50s and 60s, or even earlier, who are in the pre-symptomatic phase when the inflammatory changes are accumulating but before any cognitive decline is evident.
Identifying that population, and making a case for treating people who feel perfectly healthy, is one of the major challenges the field will face as this research moves forward.
Separately, a clinical trial is already underway at Brigham and Women’s Hospital in Boston testing a different nasal spray approach: an experimental monoclonal antibody called foralumab, developed by Tiziana Life Sciences, which also targets neuroinflammation.
Foralumab contains an experimental monoclonal antibody meant to reduce Alzheimer’s-related inflammation in the brain. The drug appears to be reducing inflammation in the brain of the first patient treated, though whether a decrease in inflammation will bring improvements in thinking and memory remains unclear.
That parallel development track matters.
Multiple research groups are converging on the same insight from different directions: that the nose is a viable delivery route to the brain, and that neuroinflammation is a viable target for early intervention.
When multiple independent lines of research arrive at the same conclusion, the signal becomes considerably more credible.
What the Body Count Is Really Telling Us
The urgency behind this research is not abstract.
Alzheimer’s disease is the sixth-leading cause of death in the United States, and deaths from the disease increased by 134 percent between 2000 and 2024, even as deaths from heart disease, stroke, and HIV decreased.
Globally, the number of people living with dementia is projected to reach over 152 million by 2050, a figure that reflects both an aging global population and the persistent absence of any treatment capable of stopping the disease.
The economic cost is staggering.
The global cost of dementia care is estimated at over one trillion dollars annually, a figure expected to more than double by 2050.
The human cost, measured in the 19.6 billion hours of unpaid care provided by family members in the US alone, is immeasurable.
Against that backdrop, a two-dose nasal spray that could delay the onset of Alzheimer’s symptoms by a decade or more is not merely a promising laboratory result.
It is potentially one of the most consequential medical developments of the century.
Dr. Shetty and his team are hopeful that this new therapy could delay Alzheimer’s symptoms by 10 to 15 years after diagnosis.
Ten to fifteen years.
For a person diagnosed with early-stage Alzheimer’s at 65, that is the difference between losing your 70s to the disease and retaining them.
For a person in their mid-50s with elevated neuroinflammatory markers, it is the difference between a disease that defines the last chapter of your life and one that might never arrive at all.
The Question Worth Sitting With
The Texas A&M nasal spray is not yet a treatment.
It is a proof of concept, backed by compelling animal data and a clear mechanistic rationale, waiting for the human trials that will determine whether the promise translates.
But the research represents something more fundamental than a single promising drug candidate.
It represents a shift in how the scientific community is beginning to think about Alzheimer’s: not as a disease that begins when memory fails, but as a biological process that begins decades earlier, driven by inflammation that is already well within reach of intervention.
The brain, it turns out, has its own repair systems.
They just need the right signal to switch on.
Whether a nasal spray can reliably provide that signal in human beings, across the staggering biological diversity of the aging population, is what the next chapter of this research will reveal.
The answer matters to everyone who has watched a parent lose themselves to this disease.
And to everyone who hopes not to.
The study, titled Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus, was published in the Journal of Extracellular Vesicles in February 2026 by researchers at the Texas A&M University Naresh K. Vashisht College of Medicine, led by Dr. Ashok K. Shetty of the Institute for Regenerative Medicine.
